Dr. Michael Yeadon is the former Vice President and Chief Scientific Advisor at Pfizer. He and Dr. Wolfgang Wodarg filed a petition with the European Medicines Agency on December 1, 2020. The petition asks the agency to halt trials for the Pfizer.
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
ASCO Endorses Guidelines on Radiation Therapy for SCLC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad .
Myriad Genetics, Inc.February 12, 2021 GMT
SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.
Penn State Health Purchases Second ViewRay MRIdian® Linac
Order is part of a Master Agreement for the Purchase of up to Four MRIdian Systems
News provided by
Share this article
Share this article
CLEVELAND, Feb. 11, 2021 /PRNewswire/ ViewRay, Inc. (Nasdaq: VRAY) announced today that Penn State Health has purchased a second MRIdian Linac joining other pioneering institutions from around the globe investing in multiple MRIdian systems. Penn State Health s first MRIdian Linac will be installed at the Penn State Health Milton S. Hershey Medical Center.
Penn State Health is a nationally ranked premier health care provider on the east coast and a world-leading medical research institution. Penn State Health approaches cancer treatment with a comprehensive, integrated program focused on education and prevention, early detection and diagnosis, and effective treatment and survivorship programs.